Beyond Air (XAIR) Set to Announce Quarterly Earnings on Monday

Beyond Air (NASDAQ:XAIR) is scheduled to be releasing its earnings data after the market closes on Monday, November 11th. Analysts expect Beyond Air to post earnings of ($0.30) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Beyond Air (NASDAQ:XAIR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.12. Beyond Air had a negative net margin of 3,272.46% and a negative return on equity of 240.15%. The company had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.72 million. During the same quarter in the previous year, the business posted ($0.45) earnings per share. On average, analysts expect Beyond Air to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Beyond Air Trading Down 6.9 %

Shares of XAIR opened at $0.47 on Friday. The company’s fifty day moving average is $0.40 and its 200 day moving average is $0.70. Beyond Air has a fifty-two week low of $0.30 and a fifty-two week high of $2.36. The stock has a market capitalization of $22.36 million, a PE ratio of -0.29 and a beta of -0.18. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.42 and a current ratio of 2.63.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on XAIR. Piper Sandler reduced their price target on shares of Beyond Air from $3.50 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Roth Capital upgraded shares of Beyond Air to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Roth Mkm restated a “buy” rating and issued a $2.00 price target on shares of Beyond Air in a research report on Friday, August 16th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $3.67.

Insider Buying and Selling at Beyond Air

In other news, CEO Steven A. Lisi acquired 1,476,626 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were acquired at an average price of $0.50 per share, for a total transaction of $738,313.00. Following the completion of the transaction, the chief executive officer now directly owns 3,249,411 shares of the company’s stock, valued at approximately $1,624,705.50. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Steven A. Lisi purchased 1,476,626 shares of Beyond Air stock in a transaction that occurred on Thursday, September 26th. The shares were bought at an average price of $0.50 per share, with a total value of $738,313.00. Following the purchase, the chief executive officer now directly owns 3,249,411 shares of the company’s stock, valued at approximately $1,624,705.50. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven A. Lisi purchased 100,000 shares of Beyond Air stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average cost of $0.39 per share, for a total transaction of $39,000.00. Following the purchase, the chief executive officer now directly owns 1,722,785 shares in the company, valued at $671,886.15. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 1,615,892 shares of company stock worth $793,019 over the last quarter. Insiders own 19.00% of the company’s stock.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.